Okmetic Oyj - Company Announcement

The Board of Directors of Okmetic Oyj supplements its statement concerning the public Tender Offer by National Silicon Industry Group and renews its recommendation

OKMETIC OYJ     STOCK EXCHANGE RELEASE     1 JUNE 2016    AT 9.30 A.M.


NOT FOR RELEASE OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN
OR INTO OR TO ANY PERSON LOCATED OR RESIDENT IN THE UNITED STATES, CANADA,
JAPAN, AUSTRALIA, SOUTH AFRICA OR HONG KONG OR IN ANY OTHER JURISDICTION IN
WHICH THE TENDER OFFER OR SUCH RELEASE OR DISTRIBUTION WOULD BE PROHIBITED BY
APPLICABLE LAW OR REQUIRE OFFER DOCUMENTS, REGISTRATION OR OTHER MEASURES IN
ADDITION TO THOSE REQUIRED UNDER FINNISH LAW.

THE BOARD OF DIRECTORS OF OKMETIC OYJ SUPPLEMENTS ITS STATEMENT CONCERNING THE
PUBLIC TENDER OFFER BY NATIONAL SILICON INDUSTRY GROUP AND RENEWS ITS
RECOMMENDATION

Okmetic Oyj ("Okmetic") announced on 1 April 2016 that Okmetic and National
Silicon Industry Group ("NSIG") had entered into a combination agreement
pursuant to which NSIG, either directly or through its subsidiary, will make a
voluntary public tender offer to purchase all of the issued and outstanding
shares and option rights in Okmetic that are not owned by Okmetic or any of its
subsidiaries (the "Tender Offer"). NSIG Finland S.à r.l (the "Offeror"), a
wholly-owned indirect subsidiary of NSIG, commenced the Tender Offer on 22 April
2016.

Pursuant to the press release published by NSIG on 30 May 2016, all the
conditions to completion of the Tender Offer have been satisfied during the
initial offer period and the Tender Offer has thus become unconditional.
According to the press release, the Offeror has decided to extend the Offer
Period to expire on 14 June 2016 at 4:00 p.m. Finnish time and has reserved a
right to further extend the Offer Period but however not beyond 30 June 2016.
According to the press release, due to the extension of the offer period, the
Offeror has decided to amend the terms and conditions of the Tender Offer to the
benefit of the shareholders and the holders of option rights, to allow
acceptances for the shares and option rights validly tendered in the Tender
Offer to be withdrawn at any time during the extended offer period or, if the
offer period has been further extended, during such further extended offer
period, despite the fact that the Offeror has declared the Tender Offer
unconditional and is obliged to complete the Tender Offer. The press release of
NSIG is attached in its entirety as Appendix 1.

NSIG and the Offeror has on 31 May 2016 published a supplement to the tender
offer document and announced that the Finnish Financial Supervisory Authority
has approved the said supplement to the tender offer document. The supplement to
the tender offer document is attached as Appendix 2. Pursuant to the supplement
to the tender offer document, the only amendment to the terms and conditions of
the Tender Offer is the above-described withdrawal right of the shareholders and
the holders of option rights.

The Board of Directors of Okmetic has on 14 April 2016 issued a statement
concerning the Tender Offer in accordance with Chapter 11, Section 13 of the
Finnish Securities Markets Act. The statement is attached as Appendix 3 to this
supplement. In its statement of 14 April 2016 the Board of Directors unanimously
recommended the shareholders and the holders of options rights of Okmetic to
accept the Tender Offer. In case an offeror amends the terms and conditions of a
tender offer, the Board of Directors of the target company is obliged, under
Chapter 11, Section 13 of the Finnish Securities Markets Act, to supplement its
statement after the amended terms and conditions have been provided to the Board
of Directors.

The Board of Directors of Okmetic has familiarised itself with the amended terms
and conditions of the Tender Offer provided in the supplement to the tender
offer document. In its evaluation, the Board of Directors of Okmetic has
considered factors such as the Finnish Financial Supervisory Authority having
approved the amendment of the terms and conditions of the Tender Offer in
accordance with the supplement to the tender offer document, the Offeror having
announced the conditions to completion of the Tender Offer to have been
satisfied and the Tender Offer having become unconditional, the Offeror being,
as set out in the supplement to the tender offer document, obliged to complete
the Tender Offer on or about 8 July 2016 at the latest, and that amendment to
the terms and conditions of the Tender Offer in the context of extending the
offer period under the Tender Offer now at hand will provide protection to the
shareholders and holders of option rights.

Based on its assessment, the Board of Directors unanimously states that
amendment to the terms and conditions of the Tender Offer in accordance with the
supplement to the tender offer document does not give rise for the Board of
Directors to amend the statement it has issued earlier concerning the Tender
Offer and that the Board of Directors renews its recommendation on the
acceptance of the Tender Offer.

The Board of Directors however draws attention to the fact that the withdrawal
right granted to the shareholders and holders of option rights under the
supplement to the tender offer document may also lead to a situation, where the
Offeror is obliged to complete the Tender Offer without having reached 90 % of
the shares and votes in Okmetic, which threshold under Chapter 18, Section 1 of
the Finnish Limited Liabilities Companies Act is a precondition for commencement
of the mandatory redemption proceedings regarding minority shares either on the
Offeror's or a minority shareholder's demand. In case the Offeror does not
obtain the portion of shares and votes required under the Finnish Limited
Liability Companies Act, neither the Offeror nor a shareholder who has not
accepted the Tender Offer (including shareholder who has withdrawn his or her
acceptance) cannot commence such redemption proceedings before the Offeror has
reached the said 90% portion.

The assessments, qualifications and remarks presented in the statement of the
Board of Directors issued on 14 April 2016 apply to this supplement.

With reference to the Helsinki Takeover Code issued by the Securities Market
Association referred to in Chapter 11, Section 28 of the Finnish Securities
Markets Act, the Board of Directors notes that none of the members of the Board
of Directors is disqualified from the consideration of the Tender Offer or its
amended terms and conditions pursuant to the Finnish Limited Liability Companies
Act. As described in the statement by the Board of Directors issued on 14 April
2016, the members of the Board of Directors have, subject to certain customary
conditions, irrevocably undertaken to accept the Tender Offer. Further, Henri
Österlund is a representative of Accendo Capital SICAV SIF fund, which fund has
also given such an undertaking. Such undertakings have been given solely in the
relevant person's capacity as a holder of shares, and it has been specifically
agreed that nothing in such undertakings limit or restrict the relevant person
(or any designee of such party who is a director of Okmetic) as a director of
Okmetic from acting in such capacity or voting in his/her sole discretion in
such capacity on any matter, however always in accordance with, where
applicable, the fiduciary duties of the Board of Directors under Finnish laws
and guidance on the board duties in the Helsinki Takeover Code. Considering the
above, the Board of Directors deems that the described undertakings do not
create such material connections to the Offeror or shared interests connected to
the Tender Offer with the Offeror, due to which the Board of Directors would not
be able to act independently and impartially in the interests of Okmetic and all
of its shareholders. All members of the Board have participated in the issuance
of this supplement to the statement.

In Helsinki, 1 June 2016

OKMETIC OYJ

Board of Directors

For further information, please contact:

Chairman of the Board Jan Lång
Phone: +358 40 508 7223, e-mail: janove.lang@outlook.com

President Kai Seikku
Phone: +358 9 5028 0232, e-mail: kai.seikku@okmetic.com

INFORMATION REGARDING OKMETIC OYJ

Established in 1985, Okmetic is one of the leading specialty silicon wafers
producers and suppliers globally with a production plant in Vantaa, Finland, and
contract manufacturers in China and Japan. The Company has sales offices in
Japan, Hong Kong and the United States as well as a diverse network of agents,
serving customers in China, South Korea, Malaysia, Singapore, Taiwan and the
United States. The tailored, high value-added silicon wafers of Okmetic are used
in the manufacture of sensors as well as discrete semiconductors and analog
circuits. Okmetic is listed on the official list of Nasdaq Helsinki (trading
code OKM1V).

Okmetic's head office is located in Vantaa. For more information visit
www.okmetic.com.

INFORMATION REGARDING NSIG

NSIG is a limited liability company organized under the PRC laws. The registered
office of NSIG is in Shanghai, China.

Established in 2015, NSIG is a China-based holding group that is engaged in the
investment and development of semiconductor materials and equipment industry
with a registered capital of RMB 2 billion (approximately EUR 272 million).
NSIG's mission is to establish a major industrial player in the global
semiconductor sector (especially silicon and its ecosystems) through both PRC
domestic investments and outbound mergers and acquisitions.

DISCLAIMER

THIS RELEASE IS FOR GENERAL INFORMATION ONLY AND DOES NOT CONSTITUTE OR FORM
PART OF ANY OFFER TO PURCHASE, OR ANY SOLICITATION OF AN OFFER TO SELL OR ANY
INVITATION TO PARTICIPATE. INVESTORS MAY ACCEPT THE TENDER OFFER FOR THE SHARES
AND OPTION RIGHTS ONLY ON THE BASIS OF THE INFORMATION PROVIDED IN A TENDER
OFFER DOCUMENT.

THE TENDER OFFER FOR THE SHARES AND OPTION RIGHTS IS NOT BEING AND WILL NOT BE
MADE DIRECTLY OR INDIRECTLY IN ANY JURISDICTION WHERE THE MAKING OF SUCH AN
OFFER OR PARTICIPATION THEREIN IS PROHIBITED BY APPLICABLE LAW OR WHICH WOULD
REQUIRE FURTHER OFFER DOCUMENTS, REGISTRATION OR OTHER MEASURES IN ADDITION TO
THOSE REQUIRED UNDER FINNISH LAW.

ACCORDINGLY, THE TENDER OFFER DOCUMENT AND RELATED ACCEPTANCE FORMS WILL NOT AND
MAY NOT BE DISTRIBUTED, FORWARDED OR TRANSMITTED INTO OR FROM ANY JURISDICTION
WHERE PROHIBITED BY APPLICABLE LAW OR WHICH WOULD REQUIRE FURTHER OFFER
DOCUMENTS, REGISTRATION OR OTHER MEASURES IN ADDITION TO THOSE REQUIRED UNDER
FINNISH LAW. IN PARTICULAR, THE TENDER OFFER FOR THE SHARES AND OPTION RIGHTS IS
NOT BEING AND WILL NOT BE MADE, DIRECTLY OR INDIRECTLY, IN OR INTO, OR BY USE OF
THE POSTAL SERVICE OF, OR BY ANY MEANS OR INSTRUMENTALITY (INCLUDING, WITHOUT
LIMITATION, FACSIMILE TRANSMISSION, TELEX, TELEPHONE, E-MAIL OR OTHER FORMS OF
ELECTRONIC COMMUNICATION) OF INTERSTATE OR FOREIGN COMMERCE OF, OR ANY
FACILITIES OF A NATIONAL SECURITIES EXCHANGE OF, THE UNITED STATES, CANADA,
JAPAN, AUSTRALIA, SOUTH AFRICA OR HONG KONG, AND MAY NOT BE ACCEPTED BY ANY SUCH
USE, MEANS, INSTRUMENTALITY OR FACILITY FROM OR WITHIN THE UNITED STATES,
CANADA, JAPAN, AUSTRALIA, SOUTH AFRICA OR HONG KONG OR BY PERSONS LOCATED OR
RESIDENT THEREIN, OR PERSONS (INCLUDING AGENTS, FIDUCIARIES OR OTHER
INTERMEDIARIES) ACTING FOR THE ACCOUNT OR BENEFIT OF PERSONS LOCATED OR RESIDENT
THEREIN. ANY PURPORTED ACCEPTANCE OF THE TENDER OFFER FOR THE SHARES AND OPTION
RIGHTS RESULTING DIRECTLY OR INDIRECTLY FROM A VIOLATION OF THESE RESTRICTIONS
WILL BE INVALID.

THE COMMUNICATION OF THIS ANNOUNCEMENT, THE TENDER OFFER DOCUMENT WHEN AVAILABLE
AND ANY OTHER DOCUMENTS OR MATERIALS RELATING TO THE TENDER OFFER IS NOT BEING
MADE AND SUCH DOCUMENTS AND/OR MATERIALS HAVE NOT BEEN APPROVED BY AN AUTHORISED
PERSON FOR THE PURPOSES OF SECTION 21 OF THE FINANCIAL SERVICES AND MARKETS ACT
2000 OF THE UNITED KINGDOM. ACCORDINGLY, SUCH DOCUMENTS AND/OR MATERIALS ARE NOT
BEING DISTRIBUTED TO, AND MUST NOT BE PASSED ON TO, THE GENERAL PUBLIC IN THE
UNITED KINGDOM. THE COMMUNICATION OF SUCH DOCUMENTS AND/OR MATERIALS AS A
FINANCIAL PROMOTION IS ONLY BEING MADE TO THOSE PERSONS IN THE UNITED KINGDOM
FALLING WITHIN THE DEFINITION OF INVESTMENT PROFESSIONALS (AS DEFINED IN ARTICLE
19(5) OF THE FINANCIAL SERVICES AND MARKETS ACT 2000 (FINANCIAL PROMOTION) ORDER
2005 (THE "FINANCIAL PROMOTION ORDER")) OR PERSONS WHO ARE WITHIN ARTICLE 43 OF
THE FINANCIAL PROMOTION ORDER OR ANY OTHER PERSONS TO WHOM IT MAY OTHERWISE
LAWFULLY BE MADE UNDER THE FINANCIAL PROMOTION ORDER.

UBS Limited is authorised by the Prudential Regulation Authority and regulated
by the Financial Conduct Authority and the Prudential Regulation Authority in
the United Kingdom. UBS Limited is acting as financial adviser to Okmetic and no
one else in connection with the Tender Offer and will not be responsible to
anyone other than Okmetic for providing the protections offered to clients of
UBS Limited nor for providing advice in connection with the Tender Offer.

APPENDIX 1: Press release of National Silicon Industry Group on 30 May 2016

NSIG FINLAND DECLARES ITS TENDER OFFER FOR ALL SHARES AND OPTION RIGHTS IN
OKMETIC UNCONDITIONAL AND EXTENDS THE ACCEPTANCE PERIOD UNTIL14 JUNE 2016

NATIONAL SILICON INDUSTRY GROUP PRESS RELEASE                     30 May 2016 at
8:30 p.m.

NOT FOR RELEASE OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN
OR INTO OR TO ANY PERSON LOCATED OR RESIDENT IN THE UNITED STATES, CANADA,
JAPAN, AUSTRALIA, SOUTH AFRICA OR HONG KONG OR IN ANY OTHER JURISDICTION IN
WHICH THE TENDER OFFER OR SUCH RELEASE OR DISTRIBUTION WOULD BE PROHIBITED BY
APPLICABLE LAW OR REQUIRE OFFER DOCUMENTS, REGISTRATION OR OTHER MEASURES IN
ADDITION TO THOSE REQUIRED UNDER FINNISH LAW.

NSIG FINLAND DECLARES ITS TENDER OFFER FOR ALL SHARES AND OPTION RIGHTS IN
OKMETIC UNCONDITIONAL AND EXTENDS THE ACCEPTANCE PERIOD UNTIL14 JUNE 2016

NSIG Finland S.à r.l ("NSIG Finland" or the "Offeror"), a wholly-owned indirect
subsidiary of National Silicon Industry Group ("NSIG"), commenced on 22 April
2016 a voluntary public tender offer to purchase all of the issued and
outstanding shares and option rights in Okmetic Oyj ("Okmetic") that are not
owned by Okmetic or any of its subsidiaries (the "Tender Offer"). The offer
period under the Tender Offer was initially scheduled to expire on 27 May 2016
(the "Offer Period").

All the conditions to completion of the Tender Offer have been satisfied during
the initial Offer Period and the Tender Offer has thus become unconditional.
Based on preliminary information on the acceptances received by 27 May 2016, the
shares tendered in the Tender Offer represent approximately 92.53 per cent of
all the shares and votes in Okmetic (excluding the treasury shares held by
Okmetic). Together with the option rights tendered, this would imply a holding
of approximately 92.46 per cent of all the shares and votes in Okmetic fully
diluted for the outstanding option rights and excluding the treasury shares held
by Okmetic.

However, the Offeror has been informed that contrary to assessments made prior
to the announcement of the Tender Offer, the relevant Ministries have indicated
that due to certain technology used by Okmetic, the completion of the Tender
Offer may, in their view, require approval of the Finnish Ministry of Employment
and the Economy under the Act on the Monitoring of Foreign Corporate
Acquisitions (172/2012). The Offeror and Okmetic will immediately take actions
to clarify the situation and aim to complete these discussions as soon as
possible. The Offeror will also make any filings necessary under said Act and
will announce further information upon any material developments in this matter.

In order to allow time for the above discussions, the Offeror has, pursuant to
the terms and conditions of the Tender Offer, decided to extend the Offer Period
to expire on 14 June 2016 at 4:00 p.m. Finnish time. Depending on the outcome of
the above discussions with the relevant Ministries, the Offeror may further
extend the Offer Period in accordance with the terms and conditions of the
Tender Offer, but not beyond 30 June 2016. However, any subsequent offer period
under the terms and conditions of the Tender Offer may extend beyond 30 June
2016 provided that the Offeror will timely complete the Tender Offer.

Assuming that the Offer Period will expire on 14 June 2016, the Offeror will
announce the final result of the Tender Offer on or about 17 June 2016, and
settlement will take place on or about 22 June 2016. Even if the Offer Period
would be further extended, the completion and the settlement of the Tender Offer
would take place on or about 8 July 2016 at the latest.

Due to the extension of the Offer Period, the Offeror has decided to amend the
terms and conditions of the Tender Offer to the benefit of the shareholders and
holders of option rights, to allow acceptances for the shares and option rights
validly tendered in the Tender Offer to be withdrawn at any time during the
extended Offer Period or, if the Offer Period has been further extended, during
such further extended Offer Period, despite the fact that the Offeror has
declared the Tender Offer unconditional and is obliged to complete the Tender
Offer.

Except for the changes to the withdrawal rights, the terms and conditions of the
Tender Offer remain unchanged. The Offeror will supplement the tender offer
document to reflect the above amendment to the terms and conditions of the
Tender Offer and will publish such supplement as soon as it has been approved by
the Finnish Financial Supervisory Authority, on or about 31 May 2016.

As all the conditions to completion of the Tender Offer have been satisfied, the
Offeror will complete the Tender Offer in accordance with its terms and
conditions after the expiry of the extended Offer Period, or any further
extended Offer Period.

"NSIG is very committed to the Tender Offer and towards Okmetic's shareholders
and will cooperate with Okmetic and the Finnish Ministry of Employment and the
Economy to clarify the above approval discussions as soon as possible. We look
forward to completing the Tender Offer and being able to support Okmetic in the
further development of its business", says Leo Ren, the managing director of
NSIG.

"The Board of Directors of Okmetic continues to unanimously support the Tender
Offer and, as required under the Finnish Securities Market Act, will supplement
its statement on the Tender Offer as soon as possible after the Offeror has
supplemented the tender offer document", says Jan Lång, Chairman of the Board of
Directors of Okmetic.

The price offered for each share validly tendered in the Tender Offer is EUR
9.20 in cash and the price offered for each option right granted under Okmetic's
option plan 2013 and validly tendered in the Tender Offer is EUR 4.87 in cash
for each 2013 A option right and EUR 4.62 in cash for each 2013 B option right
after the payment of dividend to shareholders of Okmetic on 18 April 2016.

The tender offer document (together with the supplement referred to above once
approved by the Finnish Financial Supervisory Authority) is available in the
Finnish language at the branches of Nordea Bank Finland Plc and at Nasdaq
Helsinki, Fabianinkatu 14, FI-00130 Helsinki, Finland and at the offices of NSIG
Finland, 19 rue de Bitbourg, L-1273 Luxembourg, and on the internet at
www.nordea.fi/osakkeet and www.okmetic.com/fi/sijoittajat/ostotarjous, and in
the English language on the internet at www.nordea.fi/equities and
www.okmetic.com/investors/tender-offer.

Any Okmetic shareholders or holders of option rights who have not received
information and instructions on the acceptance of the Tender Offer from their
account operator or asset manager can contact Nordea Bank Finland Plc to obtain
all necessary information and give their acceptance of the Tender Offer.

30 May 2016

National Silicon Industry Group         NSIG Finland S.à r.l.

For further information, please contact:

NSIG

Managing Director Leo Ren
Phone: +86 21 5285 9096, e-mail: leoren@sh-nsig.com

Okmetic

The Chairman of the Board Jan Lång
Phone: +358 40 508 7223, email: janove.lang@outlook.com

President Kai Seikku
Phone: +358 9 5028 0232, e-mail: kai.seikku@okmetic.com

INFORMATION REGARDING NSIG

NSIG is a limited liability company organized under the PRC laws. The registered
office of NSIG is in Shanghai, China.

Established in 2015, National Silicon Industry Group is a China-based holding
group that is engaged in the investment and development of semiconductor
materials and equipment industry with a registered capital of RMB 2 billion
(approximately EUR 272 million). NSIG's mission is to establish a major
industrial player in the global semiconductor sector (especially silicon and its
ecosystems) through both PRC domestic investments and outbound mergers and
acquisitions.

INFORMATION REGARDING OKMETIC OYJ

Established in 1985, Okmetic is one of the leading specialty silicon wafers
producers and suppliers globally with a production plant in Vantaa, Finland, and
contract manufacturers in China and Japan. The Company has sales offices in
Japan, Hong Kong and the United States as well as a diverse network of agents,
serving customers in China, South Korea, Malaysia, Singapore, Taiwan and the
United States. The tailored, high value-added silicon wafers of Okmetic are used
in the manufacture of sensors as well as discrete semiconductors and analog
circuits. Okmetic is listed on the official list of Nasdaq Helsinki (trading
code: OKM1V).

Okmetic's head office is located in Vantaa. For more information visit
www.okmetic.com.

DISCLAIMER

THIS RELEASE IS FOR GENERAL INFORMATION ONLY AND DOES NOT CONSTITUTE OR FORM
PART OF ANY OFFER TO PURCHASE, OR ANY SOLICITATION OF AN OFFER TO SELL OR ANY
INVITATION TO PARTICIPATE. INVESTORS MAY ACCEPT THE TENDER OFFER FOR THE SHARES
AND OPTION RIGHTS ONLY ON THE BASIS OF THE INFORMATION PROVIDED IN A TENDER
OFFER DOCUMENT.

THE TENDER OFFER FOR THE SHARES AND OPTION RIGHTS IS NOT BEING AND WILL NOT BE
MADE DIRECTLY OR INDIRECTLY IN ANY JURISDICTION WHERE THE MAKING OF SUCH AN
OFFER OR PARTICIPATION THEREIN IS PROHIBITED BY APPLICABLE LAW OR WHICH WOULD
REQUIRE FURTHER OFFER DOCUMENTS, REGISTRATION OR OTHER MEASURES IN ADDITION TO
THOSE REQUIRED UNDER FINNISH LAW.

ACCORDINGLY THE TENDER OFFER DOCUMENT AND RELATED ACCEPTANCE FORMS WILL NOT AND
MAY NOT BE DISTRIBUTED, FORWARDED OR TRANSMITTED INTO OR FROM ANY JURISDICTION
WHERE PROHIBITED BY APPLICABLE LAW OR WHICH WOULD REQUIRE FURTHER OFFER
DOCUMENTS, REGISTRATION OR OTHER MEASURES IN ADDITION TO THOSE REQUIRED UNDER
FINNISH LAW. IN PARTICULAR, THE TENDER OFFER FOR THE SHARES AND OPTION RIGHTS IS
NOT BEING AND WILL NOT BE MADE, DIRECTLY OR INDIRECTLY, IN OR INTO, OR BY USE OF
THE POSTAL SERVICE OF, OR BY ANY MEANS OR INSTRUMENTALITY (INCLUDING, WITHOUT
LIMITATION, FACSIMILE TRANSMISSION, TELEX, TELEPHONE, E-MAIL OR OTHER FORMS OF
ELECTRONIC COMMUNICATION) OF INTERSTATE OR FOREIGN COMMERCE OF, OR ANY
FACILITIES OF A NATIONAL SECURITIES EXCHANGE OF, THE UNITED STATES, CANADA,
JAPAN, AUSTRALIA, SOUTH AFRICA OR HONG KONG, AND MAY NOT BE ACCEPTED BY ANY SUCH
USE, MEANS, INSTRUMENTALITY OR FACILITY FROM OR WITHIN THE UNITED STATES,
CANADA, JAPAN, AUSTRALIA, SOUTH AFRICA OR HONG KONG OR BY PERSONS LOCATED OR
RESIDENT THEREIN, OR PERSONS (INCLUDING AGENTS, FIDUCIARIES OR OTHER
INTERMEDIARIES) ACTING FOR THE ACCOUNT OR BENEFIT OF PERSONS LOCATED OR RESIDENT
THEREIN. ANY PURPORTED ACCEPTANCE OF THE TENDER OFFER FOR THE SHARES AND OPTION
RIGHTS RESULTING DIRECTLY OR INDIRECTLY FROM A VIOLATION OF THESE RESTRICTIONS
WILL BE INVALID.

THE COMMUNICATION OF THIS ANNOUNCEMENT, THE TENDER OFFER DOCUMENT WHEN AVAILABLE
AND ANY OTHER DOCUMENTS OR MATERIALS RELATING TO THE TENDER OFFER IS NOT BEING
MADE AND SUCH DOCUMENTS AND/OR MATERIALS HAVE NOT BEEN APPROVED BY AN AUTHORISED
PERSON FOR THE PURPOSES OF SECTION 21 OF THE FINANCIAL SERVICES AND MARKETS ACT
2000 OF THE UNITED KINGDOM. ACCORDINGLY, SUCH DOCUMENTS AND/OR MATERIALS ARE NOT
BEING DISTRIBUTED TO, AND MUST NOT BE PASSED ON TO, THE GENERAL PUBLIC IN THE
UNITED KINGDOM. THE COMMUNICATION OF SUCH DOCUMENTS AND/OR MATERIALS AS A
FINANCIAL PROMOTION IS ONLY BEING MADE TO THOSE PERSONS IN THE UNITED KINGDOM
FALLING WITHIN THE DEFINITION OF INVESTMENT PROFESSIONALS (AS DEFINED IN ARTICLE
19(5) OF THE FINANCIAL SERVICES AND MARKETS ACT 2000 (FINANCIAL PROMOTION) ORDER
2005 (THE "FINANCIAL PROMOTION ORDER")) OR PERSONS WHO ARE WITHIN ARTICLE 43 OF
THE FINANCIAL PROMOTION ORDER OR ANY OTHER PERSONS TO WHOM IT MAY OTHERWISE
LAWFULLY BE MADE UNDER THE FINANCIAL PROMOTION ORDER.

UBS Limited is authorised by the Prudential Regulation Authority and regulated
by the Financial Conduct Authority and the Prudential Regulation Authority in
the United Kingdom. UBS Limited is acting as financial adviser to Okmetic and no
one else in connection with the Tender Offer and will not be responsible to
anyone other than Okmetic for providing the protections offered to clients of
UBS Limited nor for providing advice in connection with the Tender Offer.

APPENDIX 2: Supplement to the tender offer document

SUPPLEMENT NO. 1 TO THE TENDER OFFER DOCUMENT PUBLISHED ON 21 APRIL 2016 BY NSIG
FINLAND S.À R.L. RELATING TO THE VOLUNTARY PUBLIC TENDER OFFER FOR ALL OF THE
ISSUED AND OUTSTANDING SHARES AND OPTION RIGHTS IN OKMETIC OYJ

31 May 2016

NSIG Finland S.à r.l. ("NSIG Finland" or the "Offeror") supplements the tender
offer document published on 21 April 2016 ("Tender Offer Document") in
accordance with Chapter 11, Section 11, Subsection 4 of the Finnish Securities
Markets Act (746/2012, as amended) with the following information.

The initial offer period under NSIG Finland's voluntary public tender offer to
purchase all of the issued and outstanding shares and option rights in Okmetic
Oyj ("Okmetic") that are not owned by Okmetic or any of its subsidiaries (the
"Tender Offer") expired on 27 May 2016. All the conditions to completion of the
Tender Offer have been satisfied during the initial offer period and the Offeror
has on 30 May 2016 declared the Tender Offer unconditional.

However, the Offeror has been informed that contrary to assessments made prior
to the announcement of the Tender Offer, the relevant Ministries have indicated
that due to certain technology used by Okmetic, the completion of the Tender
Offer may, in their view, require approval of the Finnish Ministry of Employment
and the Economy under the Act on the Monitoring of Foreign Corporate
Acquisitions (172/2012). The Offeror and Okmetic have immediately taken actions
to clarify the situation and aim to complete these discussions as soon as
possible. The Offeror will also make any filings necessary under said Act.

In order to allow time for the above discussions, the Offeror has, pursuant to
the terms and conditions of the Tender Offer, on 30 May 2016 extended the offer
period to expire on 14 June 2016 at 4:00 p.m. Finnish time. Depending on the
outcome of the above discussions with the relevant Ministries, the Offeror may
further extend the offer period in accordance with the terms and conditions of
the Tender Offer, but not beyond 30 June 2016. However, any subsequent offer
period under the terms and conditions of the Tender Offer may extend beyond 30
June 2016 provided that the Offeror will timely complete the Tender Offer.
Assuming that the offer period will expire on 14 June 2016, the Offeror will
announce the final result of the Tender Offer on or about 17 June 2016, and
settlement will take place on or about 22 June 2016. Even if the Offer Period
would be further extended, the completion and the settlement of the Tender Offer
would take place on or about 8 July 2016 at the latest.

Due to the extension of the offer period, the Offeror has decided to amend the
terms and conditions of the Tender Offer to the benefit of the shareholders and
holders of option rights, to allow acceptances for the shares and option rights
validly tendered in the Tender Offer to be withdrawn at any time during the
extended offer period or, if the offer period has been further extended, during
such further extended offer period, despite the fact that the Offeror has
declared the Tender Offer unconditional and is therefore under an obligation to
complete the Tender Offer. Accordingly, the first paragraph of Section 4. "Terms
and Conditions of the Tender Offer" subsection 4.7. "Withdrawal Rights" in the
Tender Offer Document has been amended with respect to the extended offer period
to read as follows:

"The acceptances for the Shares and the Option Rights validly tendered in
accordance with the terms and conditions of the Tender Offer may be withdrawn at
any time during the extended Offer Period, even if the Offeror has declared
Tender Offer unconditional and is therefore under an obligation to complete the
Tender Offer."

Except for the changes to the withdrawal rights, the terms and conditions of the
Tender Offer remain unchanged.

The Tender Offer Document with the aforementioned supplements and amendments is
available as from 31 May 2016.

The Finnish Financial Supervisory Authority has approved the Finnish language
version of this supplement but is not responsible for the accuracy of the
information presented therein. The decision number of such approval is FIVA
7/02.05.05/2016.

APPENDIX 3: Statement by the board of directors of Okmetic Oyj concerning the
public tender offer by National Silicon Industry Group

OKMETIC OYJ      STOCK EXCHANGE RELEASE    14 APRIL 2016   AT 2.00 P.M.

NOT FOR RELEASE OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN
OR INTO OR TO ANY PERSON LOCATED OR RESIDENT IN THE UNITED STATES, CANADA,
JAPAN, AUSTRALIA, SOUTH AFRICA OR HONG KONG OR IN ANY OTHER JURISDICTION IN
WHICH THE TENDER OFFER OR SUCH RELEASE OR DISTRIBUTION WOULD BE PROHIBITED BY
APPLICABLE LAW OR REQUIRE OFFER DOCUMENTS, REGISTRATION OR OTHER MEASURES IN
ADDITION TO THOSE REQUIRED UNDER FINNISH LAW.

STATEMENT BY THE BOARD OF DIRECTORS OF OKMETIC OYJ CONCERNING THE PUBLIC TENDER
OFFER BY NATIONAL SILICON INDUSTRY GROUP

1. Background

Okmetic Oyj, ("Okmetic" or the "Company") and National Silicon Industry Group
("NSIG"), a limited liability company incorporated and existing under the laws
of the People's Republic of China, with its registered office in Shanghai,
China, have on 1 April 2016 entered into a Combination Agreement (the
"Combination Agreement"), pursuant to which NSIG, either directly or through a
wholly-owned direct or indirect subsidiary of NSIG (jointly, the "Offeror"),
will launch a voluntary public tender offer (the "Tender Offer") to purchase all
of the issued and outstanding shares and option rights in Okmetic that are not
owned by Okmetic or any of its subsidiaries. NSIG has on 1 April 2016 announced
the Tender Offer pursuant to Chapter 11 of the Finnish Securities Markets Act.

The Tender Offer will be made in accordance with the terms and conditions of a
tender offer document (the "Tender Offer Document") to be published by the
Offeror by 22 April 2016. In the Tender Offer Document the Offeror will set
forth, inter alia, (i) the background and objectives of the Tender Offer, (ii)
information on the grounds for pricing of the Tender Offer, and (iii) the terms
and conditions of the Tender Offer.

The Board of Directors of Okmetic (the "Board") has today issued this statement
(the "Statement") concerning the Tender Offer in accordance with Chapter 11,
Section 13 of the Finnish Securities Markets Act. The Statement assesses the
Tender Offer from the perspective of Okmetic, its shareholders and the holders
of its option rights as well as the Offeror's strategic plans and their probable
impact on Okmetic's operations and employment.

2. Tender Offer in Brief

In the Tender Offer, the Offeror will make a voluntary public tender offer to
purchase all of the issued and outstanding shares and option rights in Okmetic
that are not owned by Okmetic or any of its subsidiaries.

The consideration offered for each share validly tendered in the Tender Offer is
EUR 9.20 in cash. In addition, in accordance with the Combination Agreement, the
dividend of EUR 0.65 per share declared by Okmetic's Annual General Meeting held
on 7 April 2016 and to be paid to Okmetic shareholders on 18 April 2016 does not
reduce the price offered for the shares.

The share offer price of EUR 9.20 together with the dividend of EUR 0.65 per
share to be paid to Okmetic's shareholders, EUR 9.85 in the aggregate,
represents a premium of approximately 29.6 percent compared to the closing price
of the Okmetic shares on Nasdaq Helsinki Ltd ("Nasdaq Helsinki") on 31 March
2016, the last trading day before the announcement of the Tender Offer, a
premium of approximately 39.4 percent compared to the volume-weighted average
trading price of the shares on Nasdaq Helsinki during the 3-month period
preceding the announcement of the Tender Offer, and a premium of approximately
38.9 percent compared to the volume-weighted average trading price of the shares
on Nasdaq Helsinki during the 12-month period preceding the date of the
announcement of the Tender Offer. Based solely on the offer price of EUR 9.20
per share, the corresponding premium would be approximately 21.1 percent
compared to the closing price of the Okmetic shares on Nasdaq Helsinki on the
last trading day before the announcement of the Tender Offer, and approximately
30.2 percent compared to the 3-month and approximately 29.7 percent compared to
the 12-month volume-weighted average trading price of the Okmetic shares on
Nasdaq Helsinki preceding the date of the announcement of the Tender Offer.

The consideration offered for each option right granted under Okmetic's 2013
option plan and validly tendered in the Tender Offer is EUR 4.87 in cash for
each 2013 A option right and EUR 4.62 in cash for each 2013 B option right after
the payment of the dividend of EUR 0.65.

Certain of the largest shareholders of Okmetic, Accendo Capital SICAV SIF,
Ilmarinen Mutual Pension Insurance Company, Oy Ingman Finance Ab, Mandatum Life
Insurance Company Limited and Kaleva Mutual Insurance Company as well as the
members of the Board and the Executive Management Group of Okmetic (the
"Committed Shareholders"), representing jointly approximately 29.9 percent of
the outstanding shares and votes in Okmetic as well as 92.9 percent of the
outstanding option rights, have, subject to certain customary conditions,
irrevocably undertaken to accept the Tender Offer.

3. Preparation of the Statement

For the purposes of issuing the Statement, the Offeror has submitted to the
Board a draft version of the Tender Offer Document in the form in which the
Offeror has filed it with the Finnish Financial Supervisory Authority for
approval. In preparing the Statement, the Board has relied on the information
provided in the draft Tender Offer Document. The Board has not independently
verified the information included in the Tender Offer Document.

In order to support its assessment of the Tender Offer, the Board has
commissioned UBS Limited to provide an impartial fairness opinion (the "Fairness
Opinion") concerning the Tender Offer. The complete Fairness Opinion is attached
to this Statement as Appendix 1.

4. Financing of the Offer

According to the Tender Offer Document, the Offeror has secured financing for
the Tender Offer and the subsequent mandatory redemption of minority shares
through cash on NSIG's balance sheet and committed unconditional equity funding
by NSIG's shareholder. The availability of such financing is not subject to any
conditions. No third party financing is required by the Offeror to complete the
Offer and the redemption of minority shares. The Offeror may, however, at its
discretion use also third party financing for the actual settlement of the
Tender Offer. The completion of the Tender Offer is not conditional upon
obtaining financing for the Tender Offer.

5. Assessment of the Tender from the perspective of Okmetic, its shareholders
and the holders of its option rights

In evaluating the Tender Offer, analysing alternative opportunities available to
Okmetic and concluding the Statement, the Board has considered several factors,
such as Okmetic's recent financial performance, current position and future
prospects, and the historical Okmetic's share performance. The Board has
assessed the possibility of Okmetic continuing its business operations as a
standalone company and based its assessment on reasonable estimates for the
future financial performance, including Okmetic's strategic plan for the period
2016-2020. The Board has also carefully evaluated the Tender Offer and its terms
and conditions based on the draft Tender Offer Document and other available
information including:

  * the consideration and premium offered for Okmetic's outstanding shares and
    option rights;
  * valuation multiples of Okmetic's shares prior to the announcement of the
    Tender Offer;
  * the fact that the consideration will be paid in cash;
  * information and estimates of Okmetic's business operations and financial
    performance on the date of the Statement and their expected future
    development;
  * transaction certainty, including that the completion of the Tender Offer is
    not conditional upon financing or the obtaining of authority approvals;
  * the non-solicitation clause included in the Combination Agreement, with the
    ability to respond to possible third party proposals if necessary to comply
    with the Board's fiduciary duties;
  * other terms of the Tender Offer;
  * the Fairness Opinion;
  * the undertakings by the Committed Shareholders to accept the Tender Offer as
    referred to above; and
  * alternative strategic options for Okmetic.


As agreed in the Combination Agreement, the dividend of EUR 0.65 per share
declared by the Annual General Meeting of Okmetic held on 7 April 2016 and to be
paid to Okmetic shareholders on 18 April 2016 does not reduce the price offered
for the shares.

The share offer price of EUR 9.20 together with the dividend of EUR 0.65 per
share to be paid to Okmetic's shareholders, EUR 9.85 in the aggregate,
represents a premium of approximately 29.6 percent compared to the closing price
of the Okmetic shares on Nasdaq Helsinki on 31 March 2016, the last trading day
before the announcement of the Tender Offer, a premium of approximately 39.4
percent compared to the volume-weighted average trading price of the shares on
Nasdaq Helsinki during the 3-month period preceding the announcement of the
Tender Offer, and a premium of approximately 38.9 percent compared to the
volume-weighted average trading price of the shares on Nasdaq Helsinki during
the 12-month period preceding the date of the announcement of the Tender Offer.

Based solely on the offer price of EUR 9.20 per share, the consideration per
share represents a premium of approximately 21.1 percent compared to the closing
price of the Okmetic shares on Nasdaq Helsinki on 31 March 2016, the last
trading day before the announcement of the Tender Offer, a premium of
approximately 30.2 percent compared to the volume-weighted average trading price
during the 3-month period preceding the announcement of the Tender Offer, and a
premium of approximately 29.7 percent compared to the volume-weighted average
trading price during the 12-month period preceding the date of the announcement
of the Tender Offer.

Each option right entitles to subscribe for one share. The price offered for
each option right has been calculated by deducting the share subscription price
of the respective option right from the price offered for each share in the
Tender Offer and by adding the dividend of EUR 0.65 per share declared and to be
paid to Okmetic's shareholders based on the adjustment of the applicable share
subscription price in accordance with the terms and conditions of the option
rights.

According to the Fairness Opinion, attached to this Statement as Appendix 1 and
subject to the assumptions and qualifications set out therein, the consideration
offered in the Tender Offer is fair from the financial point of view for
Okmetic's shareholders and the holders of its option rights. Based on the
Fairness Opinion and the further investigations and evaluations of the Board,
the Board considers the consideration to be fair from the perspective of the
shareholders and the holders of option rights of Okmetic.

The Board has concluded that Okmetic would also have viable opportunities to
develop its business as a standalone company for the benefit of its shareholders
and the holders of its option rights. However, based on its overall assessment,
taking into consideration the factors described above, among other things, the
Board has concluded that the Tender Offer is a more favourable alternative to
Okmetic's shareholders and the holders of its option rights compared to
continuing the business operations as a standalone company or other potential
strategic alternatives available to Okmetic.

6. Evaluation of the strategic plans presented by the Offeror in the Tender
Offer Document and their probable impact on Okmetic's operations and employment

The Board has assessed the Offeror's strategic plans and their probable impact
based on the information included in the draft Tender Offer Document. According
to such information, the completion of the Tender Offer is not expected to have
any immediate effect on the business operations or assets of Okmetic. Further,
the employees and executive management of Okmetic will, according to the Tender
Offer Document, continue to play an important role in the future development of
Okmetic. The Offeror aims to retain the existing management team and employees
of Okmetic on their current employment terms in order to ensure that Okmetic
will continue on its current development path also post-Tender Offer. As
announced on 1 April 2016, Okmetic has on 31 March 2016 sold its plant located
in Allen, the United States that focused on epitaxial deposition of silicon
wafers, to American company Epitek Silicon. As a result of the sale, the
business, production facility, equipment, inventories as well as majority of the
personnel of Okmetic's US-based subsidiary Okmetic Inc. transferred to the
buyer.

According to the Tender Offer Document, the Offeror believes that there is
significant potential for market expansion globally and especially in Asia for
Okmetic.  The Offeror intends to support Okmetic by investing in R&D and
technology improvements in Finland, developing the business globally, as well as
by strengthening Okmetic's worldwide distribution platform, especially in the
rapidly growing Chinese semiconductor market. In the Tender Offer Document, the
Offeror describes that Okmetic's unique technological capabilities combined with
the Offeror's local market knowledge and access to funding, will significantly
accelerate Okmetic's development, and after the Tender Offer, with the
contribution of NSIG's experience and position in China's semiconductor and
technology-related industries and access to the funding, NSIG can provide direct
and effective added value to Okmetic's further development in the PRC and
beyond. In addition, the Offeror believes that the proven expertise and
experience of Okmetic's management and the Company's excellent financial
performance in a tough industry will continue to be major growth drivers and
success factors of the Company. The Offeror has also stated its intention to
strongly support Okmetic's growth and the future of the Vantaa plant.

The Board shares the Offeror's view that there is potential for expansion for
Okmetic's business globally and in Asia. The Board also views that Okmetic can
benefit from the Offeror's expertise and market position in the Asian market and
the Offeror's financial resources, and that they can enhance the development of
Okmetic's business in China and elsewhere in Asia e.g. through investing in its
R&D capabilities and manufacturing capacity. The Board also views that the
strong technology and know-how platform Okmetic has in Vantaa can be further
enhanced. Based on the statements in the Tender Offer Document, the Board
assesses that otherwise the impact of the strategic plans presented by the
Offeror in the Tender Offer on Okmetic's current business operations and
employment is likely to be limited.

7. Recommendation

Based on the above, the Board has unanimously decided to recommend the
shareholders and the holders of options rights of Okmetic to accept the Tender
Offer.

Notwithstanding the above, the Board also states that this Statement shall not
constitute an investment or tax advice to Okmetic's shareholders or to the
holders of its option rights, nor does the Board evaluate the general price
development or the risks relating to investments in general. Acceptance or
refusal of the Tender Offer is always a matter to be decided by the holders of
shares and option rights themselves, in which the starting point should be the
information presented by the Offeror in the Tender Offer Document.

The Board further states that Okmetic's shareholders and the holders of its
option rights should also consider the potential risks associated with not
accepting the Tender Offer. The completion of the Tender Offer would reduce the
number of Okmetic's shareholders and the number of shares that would otherwise
be publicly traded. Depending on the number of shares validly tendered in the
Tender Offer, this could have an adverse effect on the liquidity and value of
Okmetic's shares and option rights.

8. Other matters

Okmetic is committed to complying with the Helsinki Takeover Code issued by the
Securities Market Association referred to in Chapter 11 Section 28 of the
Finnish Securities Markets Act.

The Board notes that none of the Board members is disqualified from the
consideration of the Tender Offer pursuant to the Finnish Limited Liability
Companies Act. As described above, the members of the Board have, subject to
certain customary conditions, irrevocably undertaken to accept the Tender Offer.
Further, Henri Österlund is a partner and a representative of Accendo Capital
SICAV SIF which entity has also given such an undertaking. Such undertakings
have been given solely in the relevant person's capacity as a holder of shares,
and it has been specifically agreed that nothing in such undertakings limit or
restrict the relevant person (or any designee of such party who is a director of
Okmetic) as a director of Okmetic from acting in such capacity or voting in
his/her sole discretion in such capacity on any matter, however always in
accordance with, where applicable, the fiduciary duties of the Board under
Finnish laws and guidance on the board duties in the Helsinki Takeover Code.
Considering the above, the Board deems that the described undertakings do not
create such material connections to the Offeror or shared interests connected to
the Tender Offer with the Offeror, due to which the Board would not be able to
act independently and impartially in the interests of Okmetic and all of its
shareholders. All members of the Board have participated in the consideration of
the Offer and the drafting of the Statement and prepared the Board's measures
concerning the Tender Offer.

In Helsinki, 14 April 2016

OKMETIC OYJ

Board of Directors

For further information, please contact:

Chairman of the Board Jan Lång
Phone: +358 40 5087223, e-mail: janove.lang@outlook.com

President Kai Seikku
Phone: +358 9 5028 0232, e-mail: kai.seikku@okmetic.com

DISCLAIMER

THIS RELEASE IS FOR GENERAL INFORMATION ONLY AND DOES NOT CONSTITUTE OR FORM
PART OF ANY OFFER TO PURCHASE, OR ANY SOLICITATION OF AN OFFER TO SELL OR ANY
INVITATION TO PARTICIPATE. INVESTORS MAY ACCEPT THE TENDER OFFER FOR THE SHARES
AND OPTION RIGHTS ONLY ON THE BASIS OF THE INFORMATION PROVIDED IN A TENDER
OFFER DOCUMENT WHEN AVAILABLE.

THE TENDER OFFER FOR THE SHARES AND OPTION RIGHTS IS NOT BEING AND WILL NOT BE
MADE DIRECTLY OR INDIRECTLY IN ANY JURISDICTION WHERE EITHER THE MAKING OF SUCH
AN OFFER OR PARTICIPATION THEREIN IS PROHIBITED BY APPLICABLE LAW OR WHICH WOULD
REQUIRE FURTHER OFFER DOCUMENTS, REGISTRATION OR OTHER MEASURES IN ADDITION TO
THOSE REQUIRED UNDER FINNISH LAW.

ACCORDINGLY, WHEN PUBLISHED, THE TENDER OFFER DOCUMENT AND RELATED ACCEPTANCE
FORMS WILL NOT AND MAY NOT BE DISTRIBUTED, FORWARDED OR TRANSMITTED INTO OR FROM
ANY JURISDICTION WHERE PROHIBITED BY APPLICABLE LAW OR WHICH WOULD REQUIRE
FURTHER OFFER DOCUMENTS, REGISTRATION OR OTHER MEASURES IN ADDITION TO THOSE
REQUIRED UNDER FINNISH LAW. IN PARTICULAR, THE TENDER OFFER FOR THE SHARES AND
OPTION RIGHTS IS NOT BEING AND WILL NOT BE MADE, DIRECTLY OR INDIRECTLY, IN OR
INTO, OR BY USE OF THE POSTAL SERVICE OF, OR BY ANY MEANS OR INSTRUMENTALITY
(INCLUDING, WITHOUT LIMITATION, FACSIMILE TRANSMISSION, TELEX, TELEPHONE, E-
,MAIL OR OTHER FORMS OF ELECTRONIC COMMUNICATION) OF INTERSTATE OR FOREIGN
COMMERCE OF, OR ANY FACILITIES OF A NATIONAL SECURITIES EXCHANGE OF, THE UNITED
STATES, CANADA, JAPAN, AUSTRALIA, SOUTH AFRICA OR HONG KONG, AND MAY NOT BE
ACCEPTED BY ANY SUCH USE, MEANS, INSTRUMENTALITY OR FACILITY FROM OR WITHIN THE
UNITED STATES, CANADA, JAPAN, AUSTRALIA, SOUTH AFRICA OR HONG KONG OR BY PERSONS
LOCATED OR RESIDENT THEREIN, OR PERSONS (INCLUDING AGENTS, FIDUCIARIES OR OTHER
INTERMEDIARIES) ACTING FOR THE ACCOUNT OR BENEFIT OF PERSONS LOCATED OR RESIDENT
THEREIN. ANY PURPORTED ACCEPTANCE OF THE TENDER OFFER FOR THE SHARES AND OPTION
RIGHTS RESULTING DIRECTLY OR INDIRECTLY FROM A VIOLATION OF THESE RESTRICTIONS
WILL BE INVALID.

THE COMMUNICATION OF THIS ANNOUNCEMENT, THE TENDER OFFER DOCUMENT WHEN AVAILABLE
AND ANY OTHER DOCUMENTS OR MATERIALS RELATING TO THE TENDER OFFER IS NOT BEING
MADE AND SUCH DOCUMENTS AND/OR MATERIALS HAVE NOT BEEN APPROVED BY AN AUTHORISED
PERSON FOR THE PURPOSES OF SECTION 21 OF THE FINANCIAL SERVICES AND MARKETS ACT
2000 OF THE UNITED KINGDOM. ACCORDINGLY, SUCH DOCUMENTS AND/OR MATERIALS ARE NOT
BEING DISTRIBUTED TO, AND MUST NOT BE PASSED ON TO, THE GENERAL PUBLIC IN THE
UNITED KINGDOM. THE COMMUNICATION OF SUCH DOCUMENTS AND/OR MATERIALS AS A
FINANCIAL PROMOTION IS ONLY BEING MADE TO THOSE PERSONS IN THE UNITED KINGDOM
FALLING WITHIN THE DEFINITION OF INVESTMENT PROFESSIONALS (AS DEFINED IN ARTICLE
19(5) OF THE FINANCIAL SERVICES AND MARKETS ACT 2000 (FINANCIAL PROMOTION) ORDER
2005 (THE "FINANCIAL PROMOTION ORDER")) OR PERSONS WHO ARE WITHIN ARTICLE 43 OF
THE FINANCIAL PROMOTION ORDER OR ANY OTHER PERSONS TO WHOM IT MAY OTHERWISE
LAWFULLY BE MADE UNDER THE FINANCIAL PROMOTION ORDER.

UBS Limited is authorised by the Prudential Regulation Authority and regulated
by the Financial Conduct Authority and the Prudential Regulation Authority in
the United Kingdom. UBS Limited is acting as financial adviser to Okmetic and no
one else in connection with the Tender Offer and will not be responsible to
anyone other than Okmetic for providing the protections offered to clients of
UBS Limited nor for providing advice in connection with the Tender Offer.

Appendix 1: UBS Limited's Fairness Opinion

1 April 2016

The Board of Directors
Okmetic Oyj
Piitie 2, Koivuhaka, Vantaa
P.O. Box 44, FI-01301 Vantaa
Finland

Dear Sirs,

We understand that Okmetic Oyj (the "Company") is considering a transaction
whereby the Company's shareholders will receive, from National Silicon Industry
Group ("NSIG"), a cash payment in the amount of EUR 9.20 for each share validly
tendered in the Tender Offer, in exchange for all of the outstanding shares and
option rights of the Company (the "Transaction"), the terms and conditions of
which are more fully described in the offer document to be published pursuant to
the announcement of the tender offer (the "Agreement"). In addition, the
proposed dividend of EUR 0.65 per share to be declared by the Company's Annual
General Meeting to be held on 7 April 2016, shall not reduce the price offered
for the shares. In the aggregate, the Company's shareholders will as such
receive a compensation of EUR 9.85 per share (the "Consideration").

In connection with the Transaction, you have requested UBS Limited ("UBS") to
provide you with an opinion as to the fairness, from a financial point of view,
of the Consideration to be received by the shareholders of the Company.

UBS has acted as financial adviser to the Company in connection with the
Transaction and will receive a fee for its services contingent upon the
consummation of the Transaction.

From time to time, UBS, other members of the UBS Group (which for the purpose of
this letter means UBS Group AG and any subsidiary, branch or affiliate of UBS
Group AG) and their predecessors may have provided investment banking services
to the Company and NSIG or any of their affiliates un-related to the proposed
Transaction and received customary compensation for the rendering of such
services. In the ordinary course of business, UBS, UBS Group AG and their
successors and affiliates may trade securities of the Company and NSIG for their
own accounts or for the accounts of their customers and, accordingly, may at any
time hold long or short positions in such securities. An affiliate of UBS may be
acting as financier to the Company in connection with the Transaction and, in
such an event, would receive compensation in connection with such financing.

In determining our opinion we have used such customary valuation methodologies
as we have deemed necessary or appropriate for the purposes of this opinion,
including:

  * used a discounted cash flow analysis;
  * reviewed the financial position and operating results of the Company;
  * reviewed comparable companies' trading multiples; and
  * subjected the Transaction to publicly available comparisons.


Our opinion does not address the relative merits of the Transaction as compared
to other business strategies or transactions that might be available with
respect to the Company or the underlying business decision of the Company to
effect the Transaction. At your direction, we have not been asked to, nor do we,
offer any opinion as to the material terms of the Transaction, other than the
Consideration (to the extent expressly specified in this letter) under the
Agreement, or the form of the Transaction. Our opinion does not constitute an
offer by us, or represent a price at which we would be willing to purchase,
sell, enter into, assign, terminate or settle any transaction. The valuation
herein is not an indicative price quotation, in particular, it does not
necessarily reflect such factors as hedging and transaction costs, credit
considerations, market liquidity and bid-ask spreads, all of which could be
relevant in establishing an indicative price for the Company's ordinary shares.
In rendering this opinion, we have assumed, with your consent, that the
Transaction as consummated will not differ in any material respect from that
described in the draft Transaction documents we have examined (i.e. the
Agreement), without any adverse waiver or amendment of any material term or
condition thereof, and that the Company and NSIG will comply with all material
terms of the Transaction documents.

In determining our opinion, we have, among other things:

(i) reviewed certain publicly available business and historical financial
information relating to the Company;

(ii) reviewed audited financial statements of the Company;

(iii) eviewed certain internal financial information and other data relating to
the business and financial prospects of the Company, including estimates and
financial forecasts prepared by management of the Company, that were provided to
us by the Company and not publicly available and that you have directed us to
use for the purposes of our analysis;

(v) conducted discussions with, and relied on statements made by, members of the
senior management of the Company concerning the business and financial prospects
of the Company;

(vi) reviewed current and historic share prices for the Company and publicly
available financial and stock market information with respect to certain other
companies in lines of business we believe to be generally comparable to those of
the Company;

(vii) compared the financial terms of the Transaction with the publicly
available financial terms of certain other transactions which we believe to be
generally relevant;

(viii) reviewed drafts of the Transaction documents (i.e. the Agreement); and

(x) conducted such other financial studies, analyses, and investigations, and
considered such other information, as we deemed necessary or appropriate.

In connection with our review, at your direction, we have assumed and relied
upon, without independent verification, the accuracy and completeness of the
information that was publicly available or was furnished to us by or on behalf
of the Company, or otherwise reviewed by us for the purposes of this opinion,
and we have not assumed and we do not assume any responsibility or liability for
any such information. In addition, at your direction, we have not made any
independent valuation or appraisal of the assets or liabilities (contingent or
otherwise) of the Company, nor have we been furnished with any such evaluation
or appraisal.

With respect to the financial forecasts, estimates prepared by the Company as
referred to above, we have assumed, at your direction, that they have been
reasonably prepared on a basis reflecting the best currently available estimates
and judgments of the management of the Company as to the future performance of
the Company.

To the extent we have relied on publicly available financial forecasts from
various equity research analysts, we have assumed that they have been reasonably
prepared based on assumptions reflecting the best currently available estimates
and judgments by the analysts as to the expected future results of operations
and financial condition of the Company.

With respect to draft unaudited financial statements of the Company covering
periods ending prior to and dates prior to the date hereof, we have assumed that
such unaudited financial statements reflect the results that will ultimately be
reported in the audited financial statements of the Company for such periods and
dates.

We have also assumed that all governmental, regulatory or other consents and
approvals necessary for the consummation of the Transaction will be obtained
without any material adverse effect on the Company, NSIG or the Transaction. Our
opinion is necessarily based on the economic, regulatory, monetary, market and
other conditions as in effect on, and the information made available to us as
of, the date hereof (or as otherwise specified above in relation to certain
information). It should be understood that subsequent developments may affect
this opinion, which we are under no obligation to update, revise or reaffirm.

We accept no responsibility for the accounting or other data and commercial
assumptions on which this opinion is based. Furthermore, our opinion does not
address any legal, regulatory, taxation or accounting matters, as to which we
understand that the Company has obtained such advice as it deemed necessary from
qualified professionals.

Based on and subject to the foregoing, it is our opinion, as of the date hereof,
that the Consideration to be received by the shareholders of the Company in
connection with the Transaction is fair, from a financial point of view.

This letter and the opinion is provided solely for the benefit of the Board of
Directors of the Company, in their capacity as Directors of the Company, in
connection with and for the purposes of their consideration of the Transaction.
This letter is not on behalf of, and shall not confer rights or remedies upon,
may not be relied upon, and does not constitute a recommendation by UBS to, any
holder of securities of the Company or any other person other than the Board of
Directors of the Company to vote in favour of or take any other action in
relation to the Transaction.

This letter may not be used for any other purpose, or reproduced (other than for
the Board of Directors, acting in such capacity, and, on a no-reliance basis,
its advisers), disseminated or quoted at any time and in any manner without our
prior written consent.

This letter and the opinion is made without legal liability or responsibility on
our part. We accept no responsibility to any person other than the Board of
Directors of the Company in relation to the contents of this letter, even if it
has been disclosed with our consent.

Yours faithfully

UBS Limited


[HUG#2017012]

Attachments:

OKME1616_Supplement to the board statement.pdf